Summary
Medtronic plc's 2018 10-K filing highlights a year of steady net sales growth, reaching $29.95 billion, despite a slight overall percentage increase of 1%. This growth was driven by strong performance in key segments like Cardiac and Vascular, which saw a 8% increase in net sales, particularly in its Coronary & Structural Heart division. The company successfully divested its Patient Care, Deep Vein Thrombosis, and Nutritional Insufficiency businesses, generating $6.1 billion in proceeds and a $697 million gain, which significantly bolstered its liquidity and financial position. This strategic move allowed Medtronic to focus on its core growth areas and innovation pipeline. Despite facing a substantial $2.4 billion tax charge related to U.S. tax reform, Medtronic demonstrated resilience. The company's commitment to research and development remained strong, with R&D expenses totaling $2.3 billion. Furthermore, Medtronic continued to return value to shareholders, repurchasing $2.17 billion of its ordinary shares and paying $2.49 billion in dividends. The company's liquidity remains robust, with $11.2 billion in cash and current investments, supported by a $3.5 billion credit facility.
Financial Highlights
55 data points| Revenue | $29.95B |
| Cost of Revenue | $9.07B |
| Gross Profit | $20.90B |
| SG&A Expenses | $10.24B |
| Operating Income | $6.64B |
| Interest Expense | $1.15B |
| Net Income | $3.10B |
| EPS (Basic) | $2.29 |
| EPS (Diluted) | $2.27 |
| Shares Outstanding (Basic) | 1.36B |
| Shares Outstanding (Diluted) | 1.37B |
Key Highlights
- 1Net sales for fiscal year 2018 reached $29.95 billion, representing a 1% increase over the prior year, primarily driven by strong performance in the Cardiac and Vascular Group (+8%).
- 2The company divested its Patient Care, Deep Vein Thrombosis, and Nutritional Insufficiency businesses for $6.1 billion, resulting in a $697 million gain on sale.
- 3Diluted earnings per share were $2.27, significantly impacted by a $2.4 billion tax charge related to the U.S. Tax Cuts and Jobs Act.
- 4Research and development expenses were $2.25 billion, supporting innovation across the company's four operating segments.
- 5Medtronic returned $4.26 billion to shareholders through dividends ($2.49 billion) and share repurchases ($2.17 billion) during fiscal year 2018.
- 6The company maintained strong liquidity with $11.2 billion in cash and current investments, alongside a $3.5 billion credit facility.
- 7Emerging markets showed robust growth, with net sales increasing by 12% compared to the prior year.